Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

When de-extinction startup Colossal Biosciences revealed last year that it was attempting to “resurrect” the dire wolf from genetic material found in fossils, we argued that, despite the controversy surrounding the project, the company was building valuable technologies that justify its $10.2 billion valuation.

Now, roughly 16 months later, the startup is in talks to raise new funding at a $20 billion to $30 billion valuation, Axios reported.